Regardless, recent treatment advances specifically in mitochondrial diseases have shown promise in concurrently lowering GDF15 levels and mediating systemic damage, suggesting that GDF15 antagonism may provide benefit in some aspect of systemic mitochondrial disease. This evidence concerns the gene GDF15 and inborn mitochondrial metabolism disorder.